diltiazem has been researched along with Asymmetric Septal Hypertrophy, Familial in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knollmann, BC; Pauschinger, M; Potter, JD; Riad, A; Rutschow, S; Schultheiss, HP; Steendijk, P; Tschöpe, C; Westermann, D | 1 |
| Ahmad, I; Georgakopoulos, D; Giewat, M; Kass, DA; Marks, AR; McConnell, BK; Mende, U; Reiken, S; Schmitt, JP; Seidman, CE; Seidman, JG; Semsarian, C | 1 |
2 other study(ies) available for diltiazem and Asymmetric Septal Hypertrophy, Familial
| Article | Year |
|---|---|
Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy.
Topics: Analysis of Variance; Animals; Blood Pressure; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic, Familial; Collagen; Death, Sudden, Cardiac; Diltiazem; Disease Models, Animal; Heart Failure, Diastolic; Heart Rate; Mice; Mice, Transgenic; Mutation; Myocardium; Random Allocation; Treatment Outcome; Troponin T; Ventricular Function, Left | 2006 |
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calsequestrin; Cardiomyopathy, Hypertrophic, Familial; Diltiazem; Disease Models, Animal; Humans; Mice; Mice, Mutant Strains; Mutation, Missense; Myocardium; Myosin Heavy Chains; Ventricular Myosins | 2002 |